Baxter announces FDA approval of ADVATE with BAXJECT III Reconstitution System

24-04-2014 Business Wire HealthComments (0)

Baxter InternationalPharmaceuticalUSA

Baxter International (NYSE:BAX) today announced that the US Food and Drug Administration (FDA) has approved a new reconstitution system for ADVATE (Antihemophilic Factor [Recombinant]). ADVATE and the diluent come pre-packaged in the new BAXJECT III reconstitution system. ''ADVATE has the widest range of dosage formulations, allowing for more precise customized dosing, and with the ADVATE with BAXJECT III reconstitution system, patients can prepare their

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top